课题基金 / 基金详情

项目摘要

项目成果

MATCHERI S. KESHAVAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The goal of the Clinical Services Core is to support a range of projects that examine the clinical phenotypes and the endophenotypes that may be associated with the etiopathogenesis of schizophrenia. Specifically, we will study 1) a series of treatment-naive, first-episode schizophrenia patients; 2) first-episode non-schizophrenia psychotic subjects as a psychiatric comparison group; 3) adult first-degree family members of the first-episode schizophrenia patients; 4) adolescent offspring of schizophrenia patients at high risk for developing schizophrenia and related psychotic disorders; and 5) healthy comparison subjects from the same community as the patient and relative subjects. To address these goals, the Clinical Services Core will recruit and characterize the study subjects using a comprehensive diagnostic and psychopathological assessment battery, including laboratory and neuroradiological evaluations. The patients will be followed for six months to establish diagnostic stability. All data will be stored in a database managed by the Statistical and Data Management Core-D and will be accessible to Center investigators. The Core will also staff and conduct case conferences for the Brain Bank Core-B to achieve consensus diagnoses for all cases from whom post-mortem brain specimens are obtained. Data from the Clinical Services Core will be used to test the specific hypotheses regarding the etiopathophysiology of schizophrenia in Project 7-Carter and related projects funded through other mechanisms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
4/5: Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
4/5: Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
Longitudinal trajectories in treated and untreated schizophrenia
  • 批准号:
    10306962
  • 项目类别:
  • 资助金额:
    $64.17万
  • 财政年份:
    2021
  • 负责人:
    MATCHERI S. KESHAVAN
  • 依托单位:
海外基金